Screening for nephropathy and antiangiotensin use among diabetic patients in an academic community medical center

American Journal of Therapeutics

Volumn 13, Issue 1, 2006, Pages 18-23

  Frazee, Lawrence A ^a,b   Samandari, Seyhoon ^c   Tanphaichitr, Natthavat ^b   Bourguet, Claire C ^b   Pfister, Eugene W ^d  

^a AKRON GENERAL MEDICAL CENTER   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^c KING DREW MEDICAL CENTER   (United States)

^d Internal Medicine Center of Akron   (United States)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor blocker; Diabetes mellitus; Nephropathy; Screening

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE DISTRIBUTION; ALBUMINURIA; ARTICLE; COMORBIDITY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ASSESSMENT; PATIENT CARE; PREDICTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SCREENING TEST;

ACADEMIC MEDICAL CENTERS; AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRACTICE GUIDELINES; PROTEINURIA; RETROSPECTIVE STUDIES;

EID: 31544475965     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000174345.59177.9b     Document Type: Article

References (21)

1. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518-524.
2. Remuzzi G, Schieppati A, Ruggenenti P. Nephropathy in patients with type 2 diabetes. N Engl J Med. 2002;346:1145-1151.
3. Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes: ADA position statement. Diabetes Care. 2004;27(suppl 1):S79-S83.
4. Tagle R, Acevedo M, Vidt DG. Microalbuminuria: is it a valid predictor of cardiovascular risk? Cleve Clin J Med. 2003;70:255-261.
5. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
6. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephrop-athy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
7. Brenner BM, Cooper ME, DeZeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
8. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
9. Zandbergen AA, Baggen GA, Lamberts SW, et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus. Ann Intern Med. 2003;139:90-96.
10. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351:1941-1951.
11. NCQA web site. Available at: http://www.ncqa.org/Programs/HEDIS/ medicaiddiabetes00.htm.
12. NCQA web site. Available at: http://www.ncqa.org/Programs/HEDIS/ 00careavgs.htm#Comprehensive%20Diabetes%20Care.
13. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461-470.
14. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research. Belmont, CA: Lifetime Learning Publications, 1982.
15. Harris SB, Stewart M, Brown JB, et al. Type 2 diabetes in family practice. Room for improvement. Can Fam Physician. 2003;49:778-785.
16. Timpe EM, Amarshi N, Reed PJ. Evaluation of angiotensin-converting enzyme inhibitor use in patients with type 2 diabetes in a state managed care plan. Am J Manag Care. 2004;10:124-129.
17. Putzer GJ, Ramirez AM, Sneed K, et al. Prevalence of patients with type 2 diabetes mellitus reaching the American Diabetes Association's target guidelines in a university primary care setting. South Med J. 2004;97:145-148.
18. Quenan L, Remington P, Gohre F, et al. The Wisconsin collaborative diabetes quality improvement project. Wis Med J. 2000;99:48-52.
19. Sox CM, Burstin HR, Orav EJ, et al. The effect of supervision of residents on quality of care in five university-affiliated emergency departments. Acad Med. 1998;73:776-782.
20. Yusuf S, Sleight P, Pogue J, et al. Effect of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.
21. Gerstein HC, Yusuf S, Mann JFE, et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.